Impact
Overall, development of the CARE-IN-HEALTH Atlas, its application to aid decision-making processes for appropriate resolution-pharmacology through the CARE-IN-HEALTH MCDSS and, the introduction of a CARE-IN-HEALTH Biosensor to favor resolution-health will provide more appropriate and earlier cardiovascular prevention strategies with resulting health improvement. Thus, the CARE-IN-HEALTH project is designed to make a breakthrough to prevent health-to-CVD transition through a resolution of inflammation.
Specific needs
To combat chronic inflammation is a remaining challenge in CVD prevention. To be able to dampen the inflammation behind health-to-CVD transition while retaining the host defence is an unmet medical need and critical component to stay healthy. Establish the non-resolving CVD inflammation phenotype.
An optimized resolution-pharmacology in CVD prevention.
Promote resolution-health by adequate dietary counselling beyond today’s guidelines on fish intake, which is not adapted to the rapid changing society with increased vegan lifestyles and environmental concerns about marine sustainability and sea pollutions.
Expected results
Creation of the CARE-IN-HEALTH Atlas to facilitate and accelerate the global discoveries of therapeutic and preventive targets, and biomarkers, in lipiddriven/- regulated inflammation towards the resolution of inflammation without immunosuppression.
Creation of the CARE-IN-HEALTH MCDSS to be applied as for personalized medicine tool for adequate preventive measures in health care.
Creation of the CARE-IN-HEALTH Biosensor for an optimal monitoring and risk classification of citizens for a personalized dietary counselling for an optimized resolution of inflammation
D & E & C Measures
Dissemination to the scientific community and health care:
Open access CARE-IN-HEALTH Atlas Scientific publications and presentations
Exploitation:
Patenting of the CARE-IN-HEALTH MCDSS and application in a clinical proof-of-concept trial of personalized resolution-pharmacology in health care.
Patenting of the CARE-IN-HEALTH Biosensor and testing of its use in a clinical trial of dietary intervention for resolution-health,
Dissemination to citizens:
Increased awareness of resolution-health
Target groups
Subjects at high risk for CVD needing resolution-pharmacology to stay heathy
General population for adequate lifestyle counseling for a resolution-health.
Outcomes
Personalized medicine in health care for an improved CVD prevention,
Algorithms for personalized counselling and monitoring of lifestyle modifications
Impacts
Decreased CVD mortality and morbidity (accounts for 40% of all deaths within the countries of the EU).
Reduced burden on health care (estimated to €200 billion on the EU economy each year)
Increased awareness.
Adaption of healthy lifestyle counselling to a changing society.
Public Health
Compliance is a major problem with the use of drugs from which a patient does not experience an immediate perceptible effect, such as statins, which induce a lipid lowering but the beneficial effects on the quality of life and the health are not instantaneous and can only be expected after years of use. Dietary resolution health will provide long-term protection only by a personalized counseling provided by the CARE-IN-HEALTH MCDSS and the facilitated monitoring by the CARE IN-HEALTH Biosensor.
Burden on EU economy
The potential to use natural fatty acid sources to stimulate an endogenous resolution of inflammation, which emerges from CARE-IN-HEALTH, will open up for cheap and widely available resolution-pharmacology, and even to be implanted in a dietary counseling-based resolution-health at largely lower costs. We therefore argue that our approach has a favorable cost-benefits ratio because its prevention outcomes are expected to be superior and side-effects reduced. The potential improved cardiovascular prevention in health care and increased public health by citizen actions is expected to reduce the burden of CVD, with substantial financial impact.